Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11389449 | 0.82 | GAA (0.38) | GAAMAPT | |
| SCHEMBL9540291 | 0.82 | HRH4 (0.38) | GAAMEN1KMT2A | |
| SCHEMBL28831505 | 0.80 | GAA (0.39) | GAAMAPTTDP1 | |
| SCHEMBL9789197 | 0.76 | GAA (0.38) | GAAMAPT | |
| SCHEMBL9527218 | 0.76 | GAA (0.38) | GAAMAPT | |
| Hydrochloric Acid SCHEMBL8805169 | 0.74 | GAA (0.36) | GAAMAPT | |
| SCHEMBL1246857 | 0.74 | GAA (0.46) | GAAMAPTKCNH2LIPGGPR84 | |
| SCHEMBL11145199 | 0.72 | GAA (0.30) | GAAMAPT | |
| SCHEMBL10670086 | 0.70 | TRPV1 (0.36) | MAPTTDP1L3MBTL1MEN1KMT2A | |
| SCHEMBL6615020 | 0.70 | GAA (0.41) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716279-B2 | Pharmaceutical compositions of clonazepam and method of use thereof | Jazz Pharmaceuticals, Inc. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8609651-B2 | Pharmaceutical compositions of benzodiazepines and method of use thereof | Jazz Pharmaceuticals, Inc. (US) | 2013-12-17 | — | — | US | disclosed |
| EP-2056877-A2 | PHARMACEUTICAL COMPOSITIONS OF BENZODIAZEPINES AND METHODS OF USE THEREOF | Jazz Pharmaceuticals Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20080076761-A1 | Pharmaceutical compositions of clonazepam and method of use thereof | JAZZ PHARMACEUTICALS (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080070904-A1 | Pharmaceutical compositions of benzodiazepines and method of use thereof | JAZZ PHARMACEUTICALS (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2008027395-A2 | PHARMACEUTICAL COMPOSITIONS OF BENZODIAZEPINES AND METHODS OF USE THEREOF | Jazz Pharmaceuticals, Inc. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076761-A1 | Pharmaceutical compositions of clonazepam and method of use thereof | GABBR1, GABRA5, GABBR2 | GAA 1651/4885MAPT 1654/4885KCNH2 111/4885 |
| US-20080070904-A1 | Pharmaceutical compositions of benzodiazepines and method of use thereof | GABRA5, GABBR1, GABRA6 | GAA 1373/4885MAPT 1919/4885KCNH2 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.